Prospective exploratory study to describe in CHB naive and non-naive patients, hepatitis B virus (HBV) kinetics during the first 24 weeks of treatment with telbivudine.

Trial Profile

Prospective exploratory study to describe in CHB naive and non-naive patients, hepatitis B virus (HBV) kinetics during the first 24 weeks of treatment with telbivudine.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Telbivudine (Primary) ; Adefovir
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Acronyms EBEREST
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 07 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top